Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder: A Pilot Study

Martinotti, Giovanni, Sepede, Gianna, Gambi, Francesco, Di Iorio, Giuseppe, De Berardis, Domenico, Di Nicola, Marco, Onofrj, Marco, Janiri, Luigi, Di Giannantonio, Massimo · 2012 · Journal of Clinical Psychopharmacology

Abstract

The primary aim of the present study was to compare the effects of agomelatine (AGO) and venlafaxine XR (VLX) on anhedonia in patients with major depressive disorder. Secondary end points were to test its antidepressant and anxiolytic efficacy.Sixty patients were enrolled and randomly assigned to two different treatments: AGO (25-50 mg/d; n = 30 subjects) or VLX (75-150 mg/d, n = 30 subjects). Psychopathological assessment was performed at baseline and after 8 weeks of treatment with the Snaith Hamilton Rating Scale (SHAPS), the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, and the Clinical Global Impression for anhedonia, depression, anxiety, and global improvement, respectively.Both groups showed a significant reduction in time for the SHAPS, the Hamilton Depression Rating Scale, and the Hamilton Anxiety Rating Scale. A significant between-group difference was observed for SHAPS scores: patients treated with AGO showed a more relevant reduction compared with that in VLX-treated patients. Moreover, only patients treated with AGO showed a statistically significant improvement in Clinical Global Impression scores.In this study, AGO showed significantly greater efficacy on anhedonia and similar antidepressant efficacy to the serotonin-norepinephrine reuptake inhibitor VLX in patients with major depressive disorder during an 8-week treatment period. Anhedonia has been considered a potential trait marker related to vulnerability for depression. Therefore, the efficacy of AGO on this dimension holds particular importance in the treatment of patients with anhedonic features.

Overview

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e31825d6c25

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Cited by

See all 276

Metadata

Authors
Martinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M.
Affiliations
  • University of Chieti-Pescara (IT)
  • Università Cattolica del Sacro Cuore (IT)
Corresponding author
  • Martinotti, Giovanni
  • Sepede, Gianna
  • Gambi, Francesco
  • Onofrj, Marco
Venue
Journal of Clinical Psychopharmacology
Published
2012-08
Volume
32
Issue
4
Pages
487-491
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2084674758
Cited by
276
References
37
Citations by year
2026: 4 · 2025: 9 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 161 · 2019: 13 · 2018: 5 · 2017: 8 · 2016: 11 · 2015: 17 · 2014: 8 · 2013: 13 · 2012: 5
FWCI
10.11
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
agomelatine, venlafaxine, major depressive disorder, anhedonia, antidepressant efficacy, anxiolytic efficacy, serotonin-norepinephrine reuptake inhibitors, melatonin receptor agonists
MeSH terms
Venlafaxine Hydrochloride, Acetamides, Adolescent, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Depressive Disorder, Major, Female, Humans, Hypnotics and Sedatives, Male, Middle Aged, Naphthalenes, Patient Dropouts, Pilot Projects, Psychiatric Status Rating Scales, Antidepressive Agents, Second-Generation, Anhedonia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder: A Pilot Study. https://app.cochat.ai/papers/10.1097/jcp.0b013e31825d6c25
The paper
Martinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M. (2012). Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder: A Pilot Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31825d6c25

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.